Open AccessReal-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
Author(s) -
Peng Da,
Dongfeng Shan,
Chengcheng Dai,
Jie Li,
Zifan Wang,
Ziyi Huang,
Rui Peng,
Peng Zhao,
Xuezhen Ma
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s287466
Subject(s) - osimertinib , t790m , medicine , lung cancer , tolerability , oncology , gastroenterology , cancer , epidermal growth factor receptor , erlotinib , adverse effect , gefitinib
As a third-generation EGFR TKI has been taken orally, Osimertinib effectively inhibits mutant EGFR, including T790M EGFR resistance mutations. Here, we examined real-world efficacy and tolerability of Osimertinib among Chinese patients with advanced EGFR T790M-mutant NSCLC.